VERAXA Biotech Advances BiTAC Pipeline, Eyes Partnering Deals for Cancer Therapies

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update on Monday, highlighting continued advancement of its proprietary BiTAC platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs and two non-BiTAC assets available for partnering. VERAXA plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.

Company executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.

The BiTAC platform is designed to overcome limitations of conventional bispecific antibodies by incorporating a tumor-targeting arm and a T-cell engaging arm with optimized geometry and affinity, potentially improving efficacy and reducing off-target toxicity. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.

VERAXA’s pipeline update comes amid a broader surge in interest in antibody-based cancer therapies, particularly bispecific T-cell engagers and ADCs, which have shown promise in treating hematologic and solid tumors. The company’s focus on solid tumors is notable, as these represent a larger market but also present greater technical challenges due to the immunosuppressive tumor microenvironment.

By monetizing non-BiTAC assets, VERAXA aims to extend its cash runway and reduce dilution for shareholders while concentrating resources on its core platform. The company did not disclose specific financial terms or potential partners but indicated that discussions are ongoing.

For more details, the full press release is available at https://ibn.fm/xTF5q. Additional news and updates relating to VRXA can be found in the company’s newsroom at https://ibn.fm/VRXA.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech Advances BiTAC Pipeline, Eyes Partnering Deals for Cancer Therapies.

The post VERAXA Biotech Advances BiTAC Pipeline, Eyes Partnering Deals for Cancer Therapies appeared first on citybuzz.